Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1425 - IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges

    Primary Author / Presenter(s)

  • Deyan Y. Yosifov, PhD

    Division of CLL, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
    Ulm, Baden-Wurttemberg, Germany

    • Co-Author(s)

  • SR

    Sandra Robrecht

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • AG

    Adam Giza, MSc

    ST
    Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
    Cologne, Germany

  • AR

    Armin Riecke, MD

    Division of CLL, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany and Internal Medicine, Division of Hematology, German Military Hospital Ulm, Ulm, Germany
    Ulm, Baden-Wurttemberg, Germany

  • CS

    Christof Schneider, MD

    MD
    Division of CLL, Department of Internal Medicine III, University Hospital Ulm
    Ulm, Baden-Wurttemberg, Germany

  • PM

    Palash C. Maity, PhD

    Institute of Experimental Cancer Research, Ulm University Medical Center
    Ulm, Germany

  • BJ

    Billy Jebaraj, PhD

    Division of CLL, Department of Internal Medicine III, University Hospital Ulm
    Ulm, Germany

  • HJ

    Hassan Jumaa

    Institute of Immunology, Ulm University Hospital, Ulm, Germany
    Ulm, Germany

  • MY

    Marc Young

    Institute of Immunology, Ulm University Hospital, Ulm, Germany
    Ulm, Baden-Wurttemberg, Germany

  • MK

    Manish Kumar

    Institute of Experimental Cancer Research, Ulm University Medical Center, Ulm, Germany
    Ulm, Baden-Wurttemberg, Germany

  • AF

    Anna-Maria Fink

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • Kirsten Fischer

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne
    Cologne, Nordrhein-Westfalen, Germany

  • Barbara Eichhorst, MD

    Associate Professor, Consultant Hematologist
    Department I of Internal Medicine, University Hospital of Cologne
    Cologne, Germany

  • Michael Hallek, MD, PhD

    Principal Investigator, Director of Department I of Internal Medicine
    German CLL Study Group, University Hospital of Cologne
    Cologne, Germany

  • Petra Langerbeins, MD

    Faculty of Medicine and University Hospital Cologne
    Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
    Cologne, Germany

  • Stephan Stilgenbauer, MD

    Professor of Medicine, Medical Director
    Division of CLL, Internal Medicine III, Ulm University
    Ulm, Baden-Wurttemberg, Germany

  • Eugen Tausch, MD

    Treating Physician and Research Fellow
    Division of CLL, Department of Internal Medicine III, University Hospital Ulm
    Ulm, Germany